To help you advance your research, our stem cell scientists from around the world have created these presentations on cutting-edge stem cell technologies.
View our most recent webinar:
In this webinar, Dr. Gustav Holmgren describes a study that demonstrates the potential of using hiPSC-derived hepatocytes (hiPS-HEPs) as an important component in generating in vitro models of metabolic diseases such as NASH.
In this webinar, Dr. Liz Quinn of Takara Bio USA, Inc. presents data demonstrating an improved in vitro model system using our Cellartis Power Primary HEP Medium. This novel medium enables the culture of human primary hepatocytes for up to 4 weeks, allowing long-term incubation without a medium change (up to 10 days) to accurately predict in vivo intrinsic clearance.
In this webinar, Dr. Julie Estève describes the efficient generation of a hiPSC-derived hepatocyte model for primary hyperoxaluria type 1 (PH1), a rare inborn hepatic disease that is often caused by a mutation in the alanine-glyoxylate and serine-pyruvate aminotransferase (AGXT) gene.
In this webinar, Dr. Brenda Huang of Takara Bio USA, Inc. describes an improved, hiPSC-derived beta cell model that addresses the shortcomings of commonly used beta cell models. Cellartis hiPS beta cells provide an unlimited supply of mature, functional cells, and a more accurate, relevant model for diabetes research and drug development.
In this webinar, Philip Dalsbecker (Goksör-Adiels group) covers data demonstrating functional on-chip maturation of iPSCs to hepatocytes, as well as initial data showing how further optimization of the platform can give great insight into the state of the cultured cells, on single-cell and population levels.
In this webinar, Dr. Chris Sontag (Takara Bio USA, Inc.) presents data showing a new workflow for footprint-free editing via efficient delivery of Cas9/sgRNA ribonucleoprotein (RNP) complexes and single-cell cloning of hiPS cells using a modified DEF-CS culture protocol, which results in a high number of edited and expandable hiPS clones that maintain the hallmarks of pluripotency.
Dr. Christopher Sontag of Takara Bio USA, Inc. introduces single-cell cloning with the Cellartis DEF-CS 500 Culture System to create clonal hiPS cell lines. He presents data comparing the DEF-CS culture system and competitors’ systems for single-cell cloning: the DEF-CS system enables the highest survival and maintenance of pluripotency.
Ingrid Rydström, MSc, of Takara Bio Europe AB, describes solutions for maintaining human induced pluripotent stem cell lines. The Cellartis DEF-CS 500 Culture System enables the high-purity culture of hiPS cells under feeder-free, defined conditions and allows single-cell enzymatic passaging, providing unparalleled experimental flexibility. Learn about the protocol for using the DEF-CS culture system with your cells, includes passaging, guidelines for cell line transfer from other systems, and applications.
Dr. Annika Asplund (Takara Bio Europe AB) presents data generated with human iPSC-derived hepatocytes showing how we can pave the way for better disease models with more consistent performance over time. This innovative tool represents an important step toward advancing the discovery of new treatments for metabolic and infectious disease, reducing the incidence of drug-induced liver injury, and developing new strategies for liver regeneration and transplantation.
Dr. Liz Quinn of Takara Bio USA, Inc. describes the Cellartis iPS Cell to Hepatocyte Differentiation System, which provides a highly reproducible and robust hepatocyte differentiation protocol, validated on 25 different hiPS cell lines without the need for optimization. Ideal for drug metabolism and safety studies, you can start with any patient-specific hiPS cell lines and develop panels of hiPSC-derived hepatocytes with diverse genetic backgrounds.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2024 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
©2024 Takara Bio Inc. All Rights Reserved.
Region - North America Privacy Policy Terms and Conditions Terms of Use
Combining hiPSC-derived hepatocytes and bioinformatics—investigating the potential to model non-alcoholic steatohepatitis (NASH)
In this webinar, Dr. Gustav Holmgren describes a study that demonstrates the potential of using hiPSC-derived hepatocytes (hiPS-HEPs) as an important component in generating in vitro models of metabolic diseases such as NASH.
A breakthrough solution for long-term intrinsic clearance studies of low-clearance drugs
In this webinar, Dr. Liz Quinn of Takara Bio USA, Inc. presents data demonstrating an improved in vitro model system using our Cellartis Power Primary HEP Medium. This novel medium enables the culture of human primary hepatocytes for up to 4 weeks, allowing long-term incubation without a medium change (up to 10 days) to accurately predict in vivo intrinsic clearance.
Efficient generation of hiPSC-derived disease model for primary hyperoxaluria type 1
In this webinar, Dr. Julie Estève describes the efficient generation of a hiPSC-derived hepatocyte model for primary hyperoxaluria type 1 (PH1), a rare inborn hepatic disease that is often caused by a mutation in the alanine-glyoxylate and serine-pyruvate aminotransferase (AGXT) gene.
Advancing diabetes research and drug development with human iPSC-derived beta cells
In this webinar, Dr. Brenda Huang of Takara Bio USA, Inc. describes an improved, hiPSC-derived beta cell model that addresses the shortcomings of commonly used beta cell models. Cellartis hiPS beta cells provide an unlimited supply of mature, functional cells, and a more accurate, relevant model for diabetes research and drug development.
Towards a 3D liver mimicry: the liver lobule on a chip
In this webinar, Philip Dalsbecker (Goksör-Adiels group) covers data demonstrating functional on-chip maturation of iPSCs to hepatocytes, as well as initial data showing how further optimization of the platform can give great insight into the state of the cultured cells, on single-cell and population levels.
Footprint-free gene editing using CRISPR/Cas9 and single-cell cloning of edited human iPS cells
In this webinar, Dr. Chris Sontag (Takara Bio USA, Inc.) presents data showing a new workflow for footprint-free editing via efficient delivery of Cas9/sgRNA ribonucleoprotein (RNP) complexes and single-cell cloning of hiPS cells using a modified DEF-CS culture protocol, which results in a high number of edited and expandable hiPS clones that maintain the hallmarks of pluripotency.
Single-cell cloning of human iPS cells—an optimized culture system for creating highly pluripotent, edited clonal lines
Dr. Christopher Sontag of Takara Bio USA, Inc. introduces single-cell cloning with the Cellartis DEF-CS 500 Culture System to create clonal hiPS cell lines. He presents data comparing the DEF-CS culture system and competitors’ systems for single-cell cloning: the DEF-CS system enables the highest survival and maintenance of pluripotency.
A complete culture system for human induced pluripotent stem cells
Ingrid Rydström, MSc, of Takara Bio Europe AB, describes solutions for maintaining human induced pluripotent stem cell lines. The Cellartis DEF-CS 500 Culture System enables the high-purity culture of hiPS cells under feeder-free, defined conditions and allows single-cell enzymatic passaging, providing unparalleled experimental flexibility. Learn about the protocol for using the DEF-CS culture system with your cells, includes passaging, guidelines for cell line transfer from other systems, and applications.
Using human iPSC-derived hepatocytes with advanced functionality and longevity: innovative tools for disease modeling and drug discovery
Dr. Annika Asplund (Takara Bio Europe AB) presents data generated with human iPSC-derived hepatocytes showing how we can pave the way for better disease models with more consistent performance over time. This innovative tool represents an important step toward advancing the discovery of new treatments for metabolic and infectious disease, reducing the incidence of drug-induced liver injury, and developing new strategies for liver regeneration and transplantation.
Human iPSC-derived hepatocytes—innovative tools for disease modeling, drug discovery, and liver toxicity studies
Dr. Liz Quinn of Takara Bio USA, Inc. describes the Cellartis iPS Cell to Hepatocyte Differentiation System, which provides a highly reproducible and robust hepatocyte differentiation protocol, validated on 25 different hiPS cell lines without the need for optimization. Ideal for drug metabolism and safety studies, you can start with any patient-specific hiPS cell lines and develop panels of hiPSC-derived hepatocytes with diverse genetic backgrounds.
